CN112205557A - 一种降血脂药食物质固体饮料及其制备方法 - Google Patents
一种降血脂药食物质固体饮料及其制备方法 Download PDFInfo
- Publication number
- CN112205557A CN112205557A CN202010955423.4A CN202010955423A CN112205557A CN 112205557 A CN112205557 A CN 112205557A CN 202010955423 A CN202010955423 A CN 202010955423A CN 112205557 A CN112205557 A CN 112205557A
- Authority
- CN
- China
- Prior art keywords
- parts
- solid beverage
- aloe
- powder
- kudzu root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013361 beverage Nutrition 0.000 title claims abstract description 38
- 230000000055 hyoplipidemic effect Effects 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title abstract description 14
- 235000021055 solid food Nutrition 0.000 title abstract description 10
- 210000004369 blood Anatomy 0.000 claims abstract description 33
- 239000008280 blood Substances 0.000 claims abstract description 33
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 32
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 32
- 230000001603 reducing effect Effects 0.000 claims abstract description 31
- 241001105098 Angelica keiskei Species 0.000 claims abstract description 28
- 239000007787 solid Substances 0.000 claims abstract description 25
- 244000046052 Phaseolus vulgaris Species 0.000 claims abstract description 21
- 244000060011 Cocos nucifera Species 0.000 claims abstract description 18
- 235000013162 Cocos nucifera Nutrition 0.000 claims abstract description 18
- 239000004376 Sucralose Substances 0.000 claims abstract description 17
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims abstract description 17
- 235000019408 sucralose Nutrition 0.000 claims abstract description 17
- 241001116389 Aloe Species 0.000 claims abstract description 16
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 16
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 15
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 15
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 15
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 15
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 15
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 15
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 15
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 15
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 15
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 15
- 240000000249 Morus alba Species 0.000 claims abstract description 14
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 14
- 244000061458 Solanum melongena Species 0.000 claims abstract description 14
- 235000002597 Solanum melongena Nutrition 0.000 claims abstract description 14
- 235000007542 Cichorium intybus Nutrition 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 238000000227 grinding Methods 0.000 claims abstract description 9
- 244000298479 Cichorium intybus Species 0.000 claims abstract 3
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 3
- 239000000843 powder Substances 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 235000013305 food Nutrition 0.000 claims description 15
- 238000004140 cleaning Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 230000001954 sterilising effect Effects 0.000 claims description 14
- 238000005303 weighing Methods 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 13
- 235000005911 diet Nutrition 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 150000002632 lipids Chemical class 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 244000013123 dwarf bean Species 0.000 claims description 7
- 238000007710 freezing Methods 0.000 claims description 7
- 230000008014 freezing Effects 0.000 claims description 7
- 235000021332 kidney beans Nutrition 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 235000021278 navy bean Nutrition 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 7
- 238000002791 soaking Methods 0.000 claims description 7
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 7
- 230000000378 dietary effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 abstract description 27
- 229940079593 drug Drugs 0.000 abstract description 14
- 230000009286 beneficial effect Effects 0.000 abstract description 8
- 239000005556 hormone Substances 0.000 abstract description 4
- 229940088597 hormone Drugs 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 239000013543 active substance Substances 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 26
- 241001092040 Crataegus Species 0.000 description 12
- 235000012000 cholesterol Nutrition 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 11
- 241000723343 Cichorium Species 0.000 description 10
- 108010023302 HDL Cholesterol Proteins 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 8
- 239000003524 antilipemic agent Substances 0.000 description 7
- 230000018044 dehydration Effects 0.000 description 6
- 238000006297 dehydration reaction Methods 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 238000008214 LDL Cholesterol Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007102 metabolic function Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 231100000025 genetic toxicology Toxicity 0.000 description 2
- 230000001738 genotoxic effect Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 238000010953 Ames test Methods 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 201000010252 Hyperlipoproteinemia Type III Diseases 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 206010028400 Mutagenic effect Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010050208 Teratospermia Diseases 0.000 description 1
- 208000002312 Teratozoospermia Diseases 0.000 description 1
- 206010060751 Type III hyperlipidaemia Diseases 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 208000020887 hyperlipoproteinemia type 3 Diseases 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000243 mutagenic effect Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
本发明公开了一种降血脂药食物质固体饮料及其制备方法,是由下述重量份的原料制成:山楂30‑40份、芦荟25‑35份、白芸豆20‑30份、明日草20‑25份、桑叶20‑25份、葛根20‑30份、茄子10‑15份、椰子10‑15份、菊苣10‑15份,三氯蔗糖0.1‑0.5份。本发明降血脂药食物质固体饮料中没有添加任何化学药物、激素,无任何副作用,且有具有显著的降血脂功能并且采用低温破壁超细粉碎技术进行加工生产,利于保持原料中的活性物质,利于身体吸收。
Description
技术领域
本发明涉及中草药固饮料技术领域,特别涉及一种降血脂药食物质固体饮料及其制备方法。
背景技术
高脂血症是指血脂水平过高,可直接引起一些严重危害人体健康的疾病,如动脉粥样硬化、冠心病、胰腺炎等。高脂血症的治疗方法主要包括饮食治疗和药物治疗。
其中,血浆脂质主要来源于食物,通过控制饮食,可使血浆胆固醇水平降低5%~10%,同时有助于减肥。并使降脂药物发挥出最佳的效果。多数Ⅲ型高脂蛋白血症患者通过饮食治疗,同时纠正其他共存的代谢紊乱,常可使血脂水平降至正常。饮食治疗时机,主要取决于患者的冠心病危险程度和血浆LDL-胆固醇水平。一般来讲,冠心病的危险程度越高,则开始进行饮食治疗的血浆LDL-胆固醇水平就越低。高脂血症的饮食治疗是通过控制饮食的方法,在保持理想体重的同时,降低血浆中的LDL-胆固醇水平。饮食结构可直接影响血脂水平的高低。血浆胆固醇水平易受饮食中胆固醇摄入量的影响,进食大量的饱和脂肪酸也可增加胆固醇的合成。通常,肉食、蛋及乳制品等食物(特别是蛋黄和动物内脏)中的胆固醇和饱和脂肪酸含量较多,应限量进食。食用油应以植物油为主,每人每天用量以25~30g为宜。家族性高胆固醇血症患者应严格限制食物中的胆固醇和脂肪酸摄入。
药物治疗主要包括西药治疗和中药调理,西药治疗以降低血清总胆固醇和LDL胆固醇为主的有他汀类和树脂类,以降低血清三酰甘油为主的药物有贝特类和烟酸类。中药治疗的中草药制剂大都添加化学物质和激素,如以调理为目的进行长确服用,毒性较大,并且,现有的中草药制剂入口较苦,消费者接受度低。
发明内容
本发明提供了一种降血脂药食物质固体饮料及其制备方法,该降血脂药食物质固体饮料由药食同源植物和可食用植物合理配伍而成,没有添加任何化学物质和激素,无任何毒副作用,并且有具有显著的降血脂功能。
为达到上述技术目的,本发明的技术方案是这样实现的:
一种降血脂药食物质固体饮料,是由下述重量份的原料制成:山楂30-40份、芦荟25-35份、白芸豆20-30份、明日草20-25份、桑叶20-25份、葛根20-30份、茄子10-15份、椰子10-15份、菊苣10-15份,三氯蔗糖0.1-0.5份。
其中,优选地,一种降血脂药食物质固体饮料,是由下述重量份的原料制成:山楂36-38份、芦荟28-30份、白芸豆22-26份、明日草22-24份、桑叶22-24份、葛根26-28份、茄子12-14份、椰子12-14份、菊苣12-14份,三氯蔗糖0.3份。
一种降血脂药食物质固体饮料的制备方法,包括下述步骤:
(1)将葛根清洗干净、刮皮,切成片状,将切片后的葛根片置于盐水中的浸泡45分钟杀菌消毒;
(2)将步骤(1)中的葛根片烘干,并冷却至室温;
(3)将烘干冷却后的葛根片放入粉碎机中粉碎至100目细粉,得葛根粉;
(4)按配方称取白芸豆,炒制、制细粉;
(5)按配方称取桑叶、山楂、芦荟、明日草、茄子和菊苣进行清洗;
(6)将清洗后的桑叶、山楂、芦荟、明日草、茄子和菊苣进行冷冻,再采用真空冷冻干燥器进行低温脱水;
(7)将步骤(6)得到的冷冻物粉碎到100目,得混合物;
(8)取葛根粉、白芸豆粉和混合物,再加入椰子粉、三氯蔗糖,进行二次低温破壁超细粉碎至300目,灭菌、包装即得。
其中,优选地,所述步骤(1)中盐水浓度为350-480mg/kg。
其中,优选地,所述步骤(6)中低温脱水至含水量为3-7%。
其中,优选地,所述步骤(6)真空冷冻干燥的温度为30-50℃。
山楂味酸、甘,微温,主要含有山楂酸、柠檬酸、维c、脂肪分解酸,具有消食健胃,行气散瘀,促进胆固醇排泄而降低血脂的作用,是本发明配方的君药。
芦荟具有健胃、理肠、清热解毒的功效,在本发明配方中为臣药,发挥其促进血液循环、软化硬化动脉、降低胆固醇含量、扩张毛细血管的作用。
白芸豆味甘、平,具有温中下气、通利肠胃、止呃逆、益肾补元等功效。在本发明配方中为臣药,发挥其降低脂肪吸收功能,促进脂肪代谢,有效减低血液中的胆固醇含量的作用。
明日草,味甘,性温。归肝、肾、脾、胃经。在本发明配方中为臣药,发挥其改善肠胃道、降低胆固醇的作用。
茄子具有清热解暑、降脂降压、抗衰老的功效,在本发明配方中为辅佐药,发挥其降低胆固醇,防止高脂血症引起的血管损害的作用,增强山楂、芦荟、桑叶降血脂的效果。
桑叶性寒,味甘、苦,有疏散风热、清肺润燥、清肝明目的功效。在本发明配方中为辅佐药,发挥其抑制脂肪肝形成、降低血清脂肪和抑制动脉粥样硬化形成的作用,增强山楂、芦荟、白芸豆、明日草、茄子的降血脂效果。
菊苣味微苦、咸,性凉。在本发明配方中为辅佐药,发挥其清肝利胆,健胃消食,利尿消肿的作用。增强山楂、芦荟、白芸豆、明日草、桑叶、茄子的降血脂效果。
葛根甘、辛,凉。有解肌退热,生津止渴,升阳止泻之功。有“千年人参”之美誉。在本发明的配方中为辅佐药,用于减缓山楂、芦荟、白芸豆、桑叶、明日草、茄子、菊苣的药性。
椰子性味甘、平,入胃、脾、大肠经;果肉具有补虚强壮,益气祛风的功效。在本发明的配方中为辅佐药,用于减缓山楂、芦荟、白芸豆、桑叶、明日草、茄子、菊苣的药性。
本发明有益效果:
本发明针对血中总胆固醇(TC)和/或甘油三酯(TG)过高或高密度脂蛋白胆固醇(HDL-C)过低的脂肪代谢或运转异常人群缺少的维生素、微量元素进行快速补充,利于身体代谢机能的自我修复;通过身体代谢机能的调理、修复,加快清理血液中的总胆固醇(TC)和/或甘油三酯(TG),同时提高血液中的高密度脂蛋白胆固醇(HDL-C)。结合调整饮食结构和生活习惯,达到全面巩固自身代谢功能的目的。
本发明没有添加任何化学药物、激素,无任何副作用,并且采用低温破壁超细粉碎技术进行加工生产,利于保持原料中的活性物质,利于身体吸收。
服用本发明降血脂药食物质固体饮料一至四周有显著改善效果,随后根据自身情况持续或适当减量食用(一日1-3次),利于身体机能的自我调理、修复。
具体实施方式
下面对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
本实施例提供一种降血脂药食物质固体饮料,是由下述重量份的原料制成:山楂38份、芦荟32份、白芸豆28份、明日草24份、桑叶24份、葛根26份、茄子14份、椰子13份、菊苣12份,三氯蔗糖0.5份。
本实施例降血脂药食物质固体饮料的制备方法,包括下述步骤:
(1)将葛根清洗干净、刮皮,切成片状,将切片后的葛根片置于盐水中的浸泡45分钟杀菌消毒;
(2)将步骤(1)中的葛根片烘干,并冷却至室温;
(3)将烘干冷却后的葛根片放入粉碎机中粉碎至100目细粉,得葛根粉;
(4)按配方称取白芸豆,炒制、制细粉;
(5)按配方称取桑叶、山楂、芦荟、明日草、茄子和菊苣进行清洗;
(6)将清洗后的桑叶、山楂、芦荟、明日草、茄子和菊苣进行冷冻,再采用真空冷冻干燥器进行低温脱水;
(7)将步骤(6)得到的冷冻物粉碎到100目,得混合物;
(8)取葛根粉、白芸豆粉和混合物,加入椰子粉、三氯蔗糖,进行二次低温破壁超细粉碎至300目,灭菌、包装即得。
其中,所述步骤(1)中盐水浓度为400mg/kg。
其中,所述步骤(6)中低温脱水至含水量为5%。
其中,所述步骤(6)真空冷冻干燥的温度为40℃。
实施例2
本实施例提供一种降血脂药食物质固体饮料,是由下述重量份的原料制成:山楂25份、芦荟35份、白芸豆20份、明日草25份、桑叶20份、葛根30份、茄子10份、椰子15份、菊苣10份,三氯蔗糖0.5份。
本实施例降血脂药食物质固体饮料的制备方法,包括下述步骤:
(1)将葛根清洗干净、刮皮,切成片状,将切片后的葛根片置于盐水中的浸泡45分钟杀菌消毒;
(2)将步骤(1)中的葛根片烘干,并冷却至室温;
(3)将烘干冷却后的葛根片放入粉碎机中粉碎至100目细粉,得葛根粉;
(4)按配方称取白芸豆,炒制、制细粉;
(5)按配方称取桑叶、山楂、芦荟、明日草、茄子和菊苣进行清洗;
(6)将清洗后的桑叶、山楂、芦荟、明日草、茄子和菊苣进行冷冻,再采用真空冷冻干燥器进行低温脱水;
(7)将步骤(6)得到的冷冻物粉碎到100目,得混合物;
(8)取葛根粉、白芸豆粉和混合物,再加入椰子粉、三氯蔗糖,进行二次低温破壁超细粉碎至300目,灭菌、包装即得。
其中,所述步骤(1)中盐水浓度为350mg/kg。
其中,所述步骤(6)中低温脱水至含水量为3%。
其中,所述步骤(6)真空冷冻干燥的温度为30℃。
实施例3
本实施例提供一种降血脂药食物质固体饮料,是由下述重量份的原料制成:山楂40份、芦荟25份、白芸豆30份、明日草20份、桑叶25份、葛根20份、茄子15份、椰子10份、菊苣15份,三氯蔗糖0.1份。
本实施例降血脂药食物质固体饮料的制备方法,包括下述步骤:
(1)将葛根清洗干净、刮皮,切成片状,将切片后的葛根片置于盐水中的浸泡45分钟杀菌消毒;
(2)将步骤(1)中的葛根片烘干,并冷却至室温;
(3)将烘干冷却后的葛根片放入粉碎机中粉碎至100目细粉,得葛根粉;
(4)按配方称取白芸豆,炒制、制细粉;
(5)按配方称取桑叶、山楂、芦荟、明日草、茄子和菊苣进行清洗;
(6)将清洗后的桑叶、山楂、芦荟、明日草、茄子和菊苣进行冷冻,再采用真空冷冻干燥器进行低温脱水;
(7)将步骤(6)得到的冷冻物粉碎到100目,得混合物;
(8)取葛根粉、白芸豆粉和混合物,再加入椰子粉、三氯蔗糖,进行二次低温破壁超细粉碎至300目,灭菌、包装即得。
其中,所述步骤(1)中盐水浓度为480mg/kg。
其中,所述步骤(6)中低温脱水至含水量为7%。
其中,所述步骤(6)真空冷冻干燥的温度为50℃。
实施例4
本实施例提供一种降血脂药食物质固体饮料,是由下述重量份的原料制成:山楂36份、芦荟30份、白芸豆22份、明日草24份、桑叶22份、葛根28份、茄子12份、椰子肉14份、菊苣12份,三氯蔗糖0.3份。本实施例降血脂药食物质固体饮料的制备方法,包括下述步骤:
(1)将葛根清洗干净、刮皮,切成片状,将切片后的葛根片置于盐水中的浸泡45分钟杀菌消毒;
(2)将步骤(1)中的葛根片烘干,并冷却至室温;
(3)将烘干冷却后的葛根片放入粉碎机中粉碎至100目细粉,得葛根粉;
(4)按配方称取白芸豆,炒制、制细粉;
(5)按配方称取桑叶、山楂、芦荟、明日草、茄子和菊苣进行清洗;
(6)将清洗后的桑叶、山楂、芦荟、明日草、茄子和菊苣进行冷冻,再采用真空冷冻干燥器进行低温脱水;
(7)将步骤(6)得到的冷冻物粉碎到100目,得混合物;
(8)取葛根粉、白芸豆粉和混合物,再加入椰子粉、三氯蔗糖,进行二次低温破壁超细粉碎至300目,灭菌、包装即得。
其中,所述步骤(1)中盐水浓度为380mg/kg。
其中,所述步骤(6)中低温脱水至含水量为4%。
其中,所述步骤(6)真空冷冻干燥的温度为35℃。
实施例5
本实施例提供一种降血脂药食物质固体饮料,是由下述重量份的原料制成:山楂38份、芦荟28份、白芸豆22份、明日草24份、桑叶22份、葛根28份、茄子12份、椰子14份、菊苣12份,三氯蔗糖0.3份。
本实施例降血脂药食物质固体饮料的制备方法,包括下述步骤:
(1)将葛根清洗干净、刮皮,切成片状,将切片后的葛根片置于盐水中的浸泡45分钟杀菌消毒;
(2)将步骤(1)中的葛根片烘干,并冷却至室温;
(3)将烘干冷却后的葛根片放入粉碎机中粉碎至100目细粉,得葛根粉;
(4)按配方称取白芸豆,炒制、制细粉;
(5)按配方称取桑叶、山楂、芦荟、明日草、茄子和菊苣进行清洗;
(6)将清洗后的桑叶、山楂、芦荟、明日草、茄子和菊苣进行冷冻,再采用真空冷冻干燥器进行低温脱水;
(7)将步骤(6)得到的冷冻物粉碎到100目,得混合物;
(8)取葛根粉、白芸豆粉和混合物,再加入椰子粉、三氯蔗糖,进行二次低温破壁超细粉碎至300目,灭菌、包装即得。
其中,所述步骤(1)中盐水浓度为420mg/kg。
其中,所述步骤(6)中低温脱水至含水量为6%。
其中,所述步骤(6)真空冷冻干燥的温度为45℃。
按照卫生部《保健食品检验与评价技术规范》进行实验,方法及结果如下:
1.用该饮料100倍人体剂量一次性经口灌胃后,无明显的中毒表现或不良反应,2周内无动物死亡,表明本品属无毒类。
2.遗传毒性试验中,Ames试验、小鼠骨髓细胞微核试验和小鼠精子畸形实验三项遗传毒理性试验均为阴性结果,表明本品无致突变作用。
3.大鼠30d喂养实验,未引起大鼠整体健康状况、生理生化功能和器官组织形态学各重要指标的异常变。
动物功能性试验是参照中华人民共和国卫生疗卫生监督司制定的《保健食品功能学评价程序和检验方法-辅助降血脂检验方法》的规定,选用SD种成年雄性大鼠80只,以基础饲料喂养,观察10d,内疵静脉丛取血,酶法测定TC、TG和HDL-C。根据TC水平将动随机分为4组,即模型对照组和人体推荐摄入量的5倍、10倍、20倍三个剂量试验组。每组10只,各组动物喂饲高脂饲料,同时三个实验组经口灌胃给予不同剂量受试样品,连续喂养30d。最后一次灌胃24h内疵静脉丛取血,酶法测定TC、TG和HDL-C。实验前、后分别记录大鼠体重。
结果表明:以高脂饲料喂养大鼠15d,大鼠血清TC和TG水平极明显升高,表明高血脂模型成功;继续喂养30d,实验组大鼠血清HDL-C水平与对照组差异不显著;而不同剂量试验组大鼠血清TC、TG水平明显低于高血脂模型对照组(P<0.05),根据评判原则,判定本发明降血脂药食物质固体饮料对大鼠具有辅助降血脂作用。
人体试食试验中,根据受试者纳入标准选用80例患者为受试对象,测定TC、TG和HDL-C含量水平,根据血脂水平(同时考虑年龄、性别、饮食等饮食)分为实验组和对照组,实验组服用受试样品(服用方法:每天三餐前15分钟,用温水冲食固体饮料10克),对照组服用安慰剂,持续30d后,测定受试对象的TC、TG和HDL-C的含量。结果表明,与对照组相比,实验组血浆中TC降低12.8%、TG降低18.6%,HDL-C升高0.138mmol/L,根据判定原则,结果表明该苹果醋饮料具有辅助降血脂功能作用。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (6)
1.一种降血脂药食物质固体饮料,其特征在于是由下述重量份的原料制成:山楂30-40份、芦荟25-35份、白芸豆20-30份、明日草20-25份、桑叶20-25份、葛根20-30份、茄子10-15份、椰子10-15份、菊苣10-15份,三氯蔗糖0.1-0.5份。
2.根据权利要求1所述的一种降血脂药食物质固体饮料,其特征在于是由下述重量份的原料制成:山楂36-38份、芦荟28-30份、白芸豆22-26份、明日草22-24份、桑叶22-24份、葛根26-28份、茄子12-14份、椰子12-14份、菊苣12-14份,三氯蔗糖0.3份。
3.一种权利要求1或2所述的降血脂药食物质固体饮料的制备方法,其特征在于包括下述步骤:
(1)将葛根清洗干净、刮皮,切成片状,将切片后的葛根片置于盐水中的浸泡45分钟杀菌消毒;
(2)将步骤(1)中的葛根片烘干,并冷却至室温;
(3)将烘干冷却后的葛根片放入粉碎机中粉碎至100目细粉,得葛根粉;
(4)按配方称取白芸豆,炒制、制细粉;
(5)按配方称取桑叶、山楂、芦荟、明日草、茄子和菊苣进行清洗;
(6)将清洗后的桑叶、山楂、芦荟、明日草、茄子和菊苣进行冷冻,再采用真空冷冻干燥器进行低温脱水;
(7)将步骤(6)得到的冷冻物粉碎到100目,得混合物;
(8)取葛根粉、白芸豆粉和混合物,再加入椰子粉、三氯蔗糖,进行二次低温破壁超细粉碎至300目,灭菌、包装即得。
4.根据权利要求3所述的一种降血脂药食物质固体饮料的制备方法,其特征在于:所述步骤(1)中盐水浓度为350-480mg/kg。
5.根据权利要求3所述的一种降血脂药食物质固体饮料的制备方法,其特征在于:所述步骤(6)中低温脱水至含水量为3-7%。
6.根据权利要求3所述的一种降血脂药食物质固体饮料的制备方法,其特征在于:所述步骤(6)真空冷冻干燥的温度为30-50℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010955423.4A CN112205557A (zh) | 2020-09-11 | 2020-09-11 | 一种降血脂药食物质固体饮料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010955423.4A CN112205557A (zh) | 2020-09-11 | 2020-09-11 | 一种降血脂药食物质固体饮料及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112205557A true CN112205557A (zh) | 2021-01-12 |
Family
ID=74050371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010955423.4A Pending CN112205557A (zh) | 2020-09-11 | 2020-09-11 | 一种降血脂药食物质固体饮料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112205557A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112841533A (zh) * | 2021-02-01 | 2021-05-28 | 四川斯力健农业科技有限公司 | 一种减肥代餐组合物及其制备方法 |
CN113197272A (zh) * | 2021-05-18 | 2021-08-03 | 青岛三丰明日叶农业科技有限公司 | 一种可活化血管抗衰老的小肽合明日叶冻干粉饮品及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1440781A (zh) * | 2003-02-26 | 2003-09-10 | 鞍山制药有限公司 | 一种治疗心脑血管疾病的中成药心血宁 |
CN1919027A (zh) * | 2006-08-25 | 2007-02-28 | 华雪芳 | 保健饮用茶及制备方法 |
CN1939418A (zh) * | 2005-09-30 | 2007-04-04 | 张晓峰 | 一种食药同源的中草药组合物 |
CN109349384A (zh) * | 2018-11-16 | 2019-02-19 | 万顺宝(肇庆)实业有限公司 | 一种具有降低尿酸功效的神秘果复合茶及其制备方法 |
-
2020
- 2020-09-11 CN CN202010955423.4A patent/CN112205557A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1440781A (zh) * | 2003-02-26 | 2003-09-10 | 鞍山制药有限公司 | 一种治疗心脑血管疾病的中成药心血宁 |
CN1939418A (zh) * | 2005-09-30 | 2007-04-04 | 张晓峰 | 一种食药同源的中草药组合物 |
CN1919027A (zh) * | 2006-08-25 | 2007-02-28 | 华雪芳 | 保健饮用茶及制备方法 |
CN109349384A (zh) * | 2018-11-16 | 2019-02-19 | 万顺宝(肇庆)实业有限公司 | 一种具有降低尿酸功效的神秘果复合茶及其制备方法 |
Non-Patent Citations (1)
Title |
---|
韩辅: "消渴脂平治疗糖尿病合并脂代谢紊乱100例临床观察", 《中国医药指南》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112841533A (zh) * | 2021-02-01 | 2021-05-28 | 四川斯力健农业科技有限公司 | 一种减肥代餐组合物及其制备方法 |
CN113197272A (zh) * | 2021-05-18 | 2021-08-03 | 青岛三丰明日叶农业科技有限公司 | 一种可活化血管抗衰老的小肽合明日叶冻干粉饮品及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103146559B (zh) | 营养保健酒及其制备方法 | |
CN108719984B (zh) | 一种针对痛风人群的代餐营养棒及其制备方法 | |
CN104799358A (zh) | 一种风味花生酱的生产方法 | |
CN112205557A (zh) | 一种降血脂药食物质固体饮料及其制备方法 | |
CN106418501A (zh) | 一种具有减肥功能的保健食品 | |
CN104824674A (zh) | 一种防治脱发的营养保健食品 | |
CN103609701A (zh) | 一种适合脂肪肝患者饮用的酸奶及加工工艺 | |
CN103704355A (zh) | 一种低聚木糖生姜豆浆粉及其制备方法 | |
CN103609695A (zh) | 降压祛火的酸奶及其制备方法 | |
CN112190675A (zh) | 一种抗痛风药食物质固体饮料及其制备方法 | |
CN102511876B (zh) | 山楂红枣浓浆及其生产工艺 | |
CN104431434A (zh) | 一种豆渣发酵配方鸡饲料及其制备方法 | |
CN103519235A (zh) | 一种鹿肉食品 | |
CN110214902A (zh) | 一种儿童纠正偏食型富硒全营养粉 | |
CN109527565A (zh) | 一种具有减脂排毒解除便秘效果的代餐粉及其配方 | |
CN107904124A (zh) | 一种黑豆醋的生产工艺 | |
CN102511882A (zh) | 一种有助于改善生长发育的红枣浓浆 | |
CN104431433A (zh) | 一种促消化豆渣发酵鸡饲料及其制备方法 | |
KR20210041387A (ko) | 갈화 추출물 및 차전자피 분말을 함유한 숙취해소용 천연차 및 그 제조방법 | |
CN110679935A (zh) | 一种牛蒡人参精华膏及其制备方法 | |
CN109588551A (zh) | 一种治疗代谢病的饲料添加剂及其制备方法 | |
CN108783443A (zh) | 一种用于脏腑调理的片剂及其制备方法 | |
CN108967757A (zh) | 一种红枣生姜浓浆生产工艺 | |
CN106805094A (zh) | 一种谷物养生食疗组合物及其制备方法 | |
KR100804409B1 (ko) | 유황오리 만두의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210112 |